Skip to content

Biohaven BHVN Additional regulatory milestone payments

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept bhvn:AdditionalSuccessBasedMilestonePaymentsToBePaidBasedOnRegulatoryApproval.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's additional regulatory milestone payments.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's additional regulatory milestone payments?
Biohaven (BHVN) reported additional regulatory milestone payments of $60M in Q1 2026.
How has Biohaven's additional regulatory milestone payments changed year-over-year?
Biohaven's additional regulatory milestone payments decreased by 0.0% year-over-year, from $60M to $60M.